Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients

@article{Vic1996TolerancePA,
  title={Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients},
  author={Patrice Vic and Simon Jonas Ategbo and Dominique Turck and Marie Odile Husson and E. Tassin and G. A. Loeuille and Antoine Deschildre and D. Druon and J. C. Elian and C. Arrouet-Lagandre and J. P. Farriaux},
  journal={European Journal of Pediatrics},
  year={1996},
  volume={155},
  pages={948-953}
}
Twenty cystic fibrosis patients aged 1.8–22 years (mean ±SD: 9.6 ± 4.8 years) withPseudomonas aeruginosa pulmonary exacerbations were treated with amikacin (AM) (35 mg/kg/day in one daily 30 min infusion) associated with either ceftazidime (200 mg/kg/day in 3 i.v. injections) (n = 19) or imipenem (n = 1) at the same dose. Glomerular and tubular functions (creatinine clearance, 24-h proteinuria, β2 microglobulinuria, lysozymuria) and audiometry remained within normal ranges from day 0 to day 14… CONTINUE READING
8 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Sputum penetration of a single daily dose of amikacin and a continuous infusion of ceftazidime in cystic fibrosis patients

  • B Byl, D Baran, +4 authors JP Thys
  • ICAAC (Anaheim); Abstract
  • 1992
2 Excerpts

Antibiotic therapy in cystic fibrosis : evaluation of clinical trials

  • AL Smith
  • J Pediatr
  • 1986

Similar Papers

Loading similar papers…